Tags: Cancer | leukemia | drug | roche | venetoclax

New Leukemia Drug Is 'Breakthrough': FDA

Thursday, 07 May 2015 08:14 AM

Swiss drugmaker Roche said on Thursday the U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation for venetoclax for the treatment of people who have relapsed or refractory chronic lymphocytic leukemia with a genetic abnormality.

"We are pleased that the FDA has granted venetoclax breakthrough therapy designation and hope this regulatory pathway will help us bring venetoclax to people with this difficult-to-treat disease soon," Roche Chief Medical Officer and Head of Global Clinical Development Sandra Horning said in a statement.

Breakthrough therapy designation is given when early data shows a product may confer substantial improvement over existing therapies.

© 2020 Thomson/Reuters. All rights reserved.

   
1Like our page
2Share
Health-News
Swiss drugmaker Roche said on Thursday the U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation for venetoclax for the treatment of people who have relapsed or refractory chronic lymphocytic leukemia with a genetic abnormality. We are...
leukemia, drug, roche, venetoclax
100
2015-14-07
Thursday, 07 May 2015 08:14 AM
Newsmax Media, Inc.
 

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved